Orsaria Maria, Londero Ambrogio P, Marzinotto Stefania, Di Loreto Carla, Marchesoni Diego, Mariuzzi Laura
Department of Medical and Biological Sciences, DSMB, University of Udine, Udine, Italy.
Unit of Obstetrics and Gynecology, Hospital of Monfalcone (GO), Italy.
Cancer Biomark. 2016;17(4):479-486. doi: 10.3233/CBM-160665.
To analyze the expression profile of placental type alkaline phosphatase (PLAP), cancer antigen 125 (CA125), and human epididymis protein 4 (HE4) in serous ovarian cancer and to correlate their expression with the tumor aggressiveness and progression.
Retrospective study considering a tissue microarray of 82 women affected by ovarian serous cancer. Protein expression was assessed by immunohistochemistry on ovarian serous cancer tissue samples. Immunohistochemical staining was semiquantitatively evaluated as H-score.
Median H-score values were lower for PLAP, 1 (IQR 0-4) than CA125, 10 (IQR 6-12) or HE4, 8 (IQR 5-12). Even if PLAP was less expressed in the cells of serous ovarian cancer than CA125 or HE4 it was relatively more expressed in the fourth quartile of its H-score distribution among cases with low CA125 or HE4 expression. Furthermore, PLAP and HE4 high expression resulted to be significantly correlated with a better prognosis.
PLAP could be an additional marker for early detection of serous ovarian carcinoma, together with the established CA125 and HE4. In addition, PLAP expression is correlated with prognosis, giving, in this way, an additional tool for improving treatment approach.
分析胎盘型碱性磷酸酶(PLAP)、癌抗原125(CA125)和人附睾蛋白4(HE4)在浆液性卵巢癌中的表达谱,并将它们的表达与肿瘤侵袭性和进展相关联。
对82例浆液性卵巢癌女性患者的组织芯片进行回顾性研究。通过免疫组织化学方法评估浆液性卵巢癌组织样本中的蛋白表达。免疫组织化学染色采用H评分进行半定量评估。
PLAP的H评分中位数为1(四分位间距0 - 4),低于CA125的10(四分位间距6 - 12)或HE4的8(四分位间距5 - 12)。即使PLAP在浆液性卵巢癌细胞中的表达低于CA125或HE4,但在CA125或HE4低表达病例中,其H评分分布的第四个四分位数中表达相对较高。此外,PLAP和HE4高表达与较好的预后显著相关。
PLAP可能是浆液性卵巢癌早期检测的一个额外标志物,与已确立的CA125和HE4一起。此外,PLAP表达与预后相关,从而为改进治疗方法提供了一个额外的工具。